key: cord-0688983-asd9zr0n
authors: Kitamura, Naoya; Sacco, Michael Dominic; Ma, Chunlong; Hu, Yanmei; Townsend, Julia Alma; Meng, Xiangzhi; Zhang, Fushun; Zhang, Xiujun; Ba, Mandy; Szeto, Tommy; Kukuljac, Adis; Marty, Michael Thomas; Schultz, David; Cherry, Sara; Xiang, Yan; Chen, Yu; Wang, Jun
title: Expedited Approach toward the Rational Design of Noncovalent SARS-CoV-2 Main Protease Inhibitors
date: 2021-04-23
journal: J Med Chem
DOI: 10.1021/acs.jmedchem.1c00509
sha: 06f579bca6e65319d676ceec99f33c7e0b7a1809
doc_id: 688983
cord_uid: asd9zr0n

[Image: see text] The main protease (M(pro)) of SARS-CoV-2 is a validated antiviral drug target. Several M(pro) inhibitors have been reported with potent enzymatic inhibition and cellular antiviral activity, including GC376, boceprevir, calpain inhibitors II, and XII, with each containing a reactive warhead that covalently modifies the catalytic Cys145. Coupling structure-based drug design with the one-pot Ugi four-component reaction, we discovered one of the most potent noncovalent inhibitors, 23R (Jun8-76-3A) that is structurally distinct from the canonical M(pro) inhibitor GC376. Significantly, 23R is highly selective compared with covalent inhibitors such as GC376, especially toward host proteases. The cocrystal structure of SARS-CoV-2 M(pro) with 23R revealed a previously unexplored binding site located in between the S2 and S4 pockets. Overall, this study discovered 23R, one of the most potent and selective noncovalent SARS-CoV-2 M(pro) inhibitors reported to date, and a novel binding pocket in M(pro) that can be explored for inhibitor design.

The COVID-19 pandemic had a significant impact on the global economy and public health, and there is an urgent need for therapeutic interventions. The viral polymerase inhibitor remdesivir gained FDA approval on October 22nd, 2020. The combination therapy of remdesivir with the Janus kinase (JAK) inhibitor baricitinib also received FDA emergency use authorization. 1 Among the other drug targets being pursued at preclinical and clinical stages, 2 the viral main protease (M pro ), also called 3-chymotrypsin-like protease (3CL pro ), is one of the most extensively explored high profile antiviral drug targets. 3 M pro is a cysteine protease encoded in the viral polyprotein as nonstructural protein 5 (Nsp5) that cleaves the viral polyproteins pp1a and pp1ab at more than 11 sites. Despite its multiple proteolytic sites, M pro was shown to have a high substrate specificity of glutamine at the P1 position. 4 As such, the majority of the reported M pro inhibitors were designed to contain a 2-pyrrolidone at the P1 substitution as a mimetic of the glutamine in the substrate. 5 Most advanced M pro inhibitors including PF-07304814, 6 GC376, 7,8 6j, 9 MI-09, and MI-30 10 all belong to this category ( Figure 1 ). PF-07304814, an α-hydroxyl ketone prodrug, is being developed by Pfizer and has optimal pharmacokinetic properties and recently entered human clinical trials. 6 GC376 has in vivo antiviral efficacy in treating cats infected with lethal feline infectious peritonitis virus. 11, 12 Recently, the GC376 analog 6j was shown to protect mice from MERS-CoV infection. 9 MI-09 and MI-30 were shown to protect mice from lethal SARS-CoV-2 infection. 10 These promising results highlight the translational potential of M pro inhibitors as potent SARS-CoV-2 antivirals and validate M pro as an antiviral drug target for coronaviruses.

Drug discovery is a lengthy process involving iterative cycles of design, synthesis, and pharmacological characterization. In the event of the COVID-19 pandemic, an expedited approach with a fast turnover of this development cycle is highly desired. Using SARS-CoV-2 M pro as a drug target, we report herein a fast-track drug discovery approach by coupling structure-based drug design and the Ugi four-component reaction (Ugi-4CR) methodology. The design was based on the superimposed structures of SARS-CoV or SARS-CoV-2 M pro in complex with inhibitors including GC376, calpain inhibitor XII, and ML188 (R). 7, 8, 13 The lead compound 23R from this study is the most potent noncovalent SARS-CoV-2 M pro inhibitor reported to date in terms of enzymatic inhibition and cellular antiviral activity. The target selectivity of the designed inhibitors was profiled against a panel of viral proteases and host proteases, and the noncovalent inhibitor 23R was found to be highly selective compared to the covalent inhibitor GC376. An X-ray crystal structure of SARS-CoV-2 M pro in complex with 23R was solved, revealing a drug-induced conformational change and a previously unexplored binding site in between the S2 and S4 pockets. Overall, this study led to the discovery of the noncovalent M pro inhibitor 23R with potent enzymatic inhibition and in vitro cellular antiviral activity with a novel mechanism of action.

■ RESULTS AND DISCUSSION Rational Design of Noncovalent SARS-CoV-2 M pro Inhibitors. Among the noncanonical SARS-CoV-2 M pro inhibitors we recently discovered, calpain inhibitor XII has an unexpected binding mode showing an inverted conformation in the active site ( Figure 2A ). 8 Instead of projecting the norvaline and leucine side chains into the S1 and S2 pockets as one would expect from its chemical structure, the pyridinyl substitution snuggly fits in the S1 pocket and forms a hydrogen bond with the H163 imidazole ( Figure 2A ). This hydrogen bond is essential, as replacing the pyridine with benzene led to an analog UAWJ257 with a significant loss of enzymatic inhibition. 8 Examining the X-ray crystal structures of SARS-CoV and SARS-CoV-2 M pro in the PDB database revealed another compound ML188 (R), 13 which shares a similar binding mode with calpain inhibitor XII. ML188 (R) is a noncovalent SARS-CoV M pro inhibitor derived from a highthroughput screening hit. 13 The pyridinyl from ML188 (R) similarly fits in the S1 pocket and forms a hydrogen bond with the H163 side chain imidazole ( Figure 2B ). In addition, the furyl oxygen and its amide oxygen both form a hydrogen bond with the G143 main chain amide amine. ML188 (R) was reported to inhibit the SARS-CoV M pro with an IC 50 value of 1.5 ± 0.3 μM and the SARS-CoV viral replication in Vero E6 cells with an EC 50 value of 12.9 μM. 13 Several follow up studies have been conducted to optimize the enzymatic inhibition and cellular antiviral activity of this series of compounds; however, no significant improvement has been made. 14, 15 The similar binding mode of ML188 (R) with calpain inhibitor XII, coupled with the convenient synthesis through the one pot Ugi-4CR, inspired us to design noncovalent SARS- CoV-2 M pro inhibitors based on the ML188 (R) scaffold. Specifically, we leverage our understanding of the M pro inhibition mechanism based on the X-ray crystal structures of SARS-CoV-2 M pro with multiple inhibitors to guide the lead optimization ( Figure 3A −D). 7, 8 Overlaying the X-ray crystal structures of SARS-CoV M pro + ML188 (R) (PDB: 3V3M) and the SARS-CoV M pro H41A mutant + the peptide substrate (PDB: 2Q6G) revealed that the furyl, 4-tert-butylphenyl, pyridinyl, and tert-butyl of ML188 (R) fit in the S1′, S2, S1, and S3 pockets, respectively ( Figure 3A, D) . Therefore, the furyl, 4-tert-butylphenyl, pyridinyl, and tert-butyl substitutions in ML188 (R) were defined as P1′, P2, P1, and P3, respectively. Next, overlaying the structure of SARS-CoV M pro + ML188 (R) (PDB: 3V3M) and SARS-CoV-2 M pro + GC376 (PDB: 6WTT) suggested that the tert-butyl at the P3 substitution of ML188 (R) can be extended to fit in the S4 pocket ( Figure 3B , D). Previous structure−activity relationship studies of GC376 indicate that P4 substitution is important, while P3 substitution does not contribute significantly to the binding affinity, as it is solvent exposed. 3, 8, 9, 16 Similarly, the overlaying structures of SARS-CoV M pro + ML188 (R) (PDB: 3V3M) and SARS-CoV-2 M pro + UAWJ247 (PDB: 6XBH) suggested that the 4-tert-butyl at the P2 substitution of ML188 (R) can be replaced by phenyl to occupy the extra space in the S2 pocket ( Figure 3C, D) . Overall, binding site analysis suggests that extending the P2 and P3 substitutions of ML188 (R) might lead to better shape complementarity with the SARS-CoV-2 M pro ( Figure 3E ). In practice, we adopted a stepwise optimization procedure in which the P3 and P2 substitutions were optimized individually in step 1 and then the optimal P2/P3 substitutions were combined in step 2 ( Figure 3E ).

Guided by the design rationale elucidated above, a focused library of ML188 analogs was designed and synthesized ( Figure 4 ). As the P1′ furyl and P1 pyridinyl both form a critical hydrogen bond with the M pro ( Figure 4A , B), the P1′ and P1 substitutions were kept with minimal variations for the design of noncovalent inhibitors ( Figure 4C ). All designed compounds were synthesized using the one pot Ugi fourcomponent reaction and tested as enantiomer/diastereomer mixtures ( Figure 4C ). To circumvent the need of relying on an expensive chiral HPLC column for the separation of enantiomers, we strategically introduced the chiral isocyanide so that the diastereomer product mixture can be separated by convenient silica gel column or reverse phase HPLC column purification. 17 Structure−Activity Relationship Studies of Noncovalent SARS-CoV-2 M pro Inhibitors. In total, 39 compounds were synthesized (Figure 5A−E) and all compounds were initially tested as a mixture of enantiomers or diastereomers in the FRET-based enzymatic assay against SARS-CoV-2 M pro at 20 μM ( Figure 5F ). Compounds showing more than 50% inhibition at 20 μM were further titrated to determine the IC 50 values. Next, compounds with IC 50 values lower than 5 μM were selected for cellular cytotoxicity profiling in Vero E6 cells, the cell line which was used for the SARS-CoV-2 antiviral assay. The purpose was to prioritize lead candidates for the in vitro cellular antiviral assay with infectious SARS-CoV-2. As shown in Figure 5 , the majority of the designed compounds showed more than 50% inhibition when tested at 20 μM. Specifically, Figure 5A lists compounds with P4 variations. As a reference, ML188 (1) (racemic mixture) inhibits SARS-CoV-2 M pro with an IC 50 value of 10.96 ± 1.58 μM. It was found that compounds 2, 3, 5, 6, 7, 8, 10, and 13 had improved enzymatic inhibition compared to ML188 (1). These results suggest that (a) isopropyl (2), cyclopropyl (3), cyclopentyl (5), cyclohexyl (6) , and phenyl (7 and 8) are the more favorable substitutions at the P3 position than tert-butyl and (b) compound 13 with the (S)-α-methylbenzyl substitution at the P3 position had improved potency, which suggests that extending the substitutions to the S4 pocket might improve the enzymatic inhibition ( Figure 3B ). Given the advantage of convenient separation of diastereomers over enantiomers, we therefore decided to fix the P3/P4 substitution as α-methylbenzyl substitution during the P2 optimization ( Figure 5B ). All compounds in Figure 5B were designed to have extended substitutions at the 4-position of benzyl to occupy the extra space in the S2 pocket ( Figure 3C ). Consistent with the design hypothesis, several compounds including 14, 17, 18, 19, 20, 21 , and 23 had significantly improved enzymatic inhibition (IC 50 < 3 μM) compared to compound 13. Replacing the tert-butyl in compound 13 with the bulkier trimethylsilyl led to compound 14 with a 2.9-fold increase in M pro inhibition. Cyclohexyl (17) , thienyl (19) , pyrrolyl (20) , pyridinyl (21) , and phenyl (23) were found to be the most favorable substitutions at the S2 pocket. Compound 16 with piperidyl substitution had similar potency as compound 13, while compound 15 with O-tert butyl was less active. Further extending the substitution to benzyl led to compound 22 that was inactive, suggesting biphenyl might be the longest substitution that can be accommodated at the S2 pocket.

The P1′ and P1 substitutions ( Figure 5C , D) were chosen to retain the critical hydrogen bonds in ML188 ( Figure 4A ). It was found that imidazole (24) was tolerated at the P1′ position (IC 50 = 0.96 ± 0.09 μM), followed by isoxazole (25) (IC 50 = 2.47 ± 0.27 μM) and oxazole (26) (IC 50 = 4.97 ± 0.78 μM). Pyrazine (27) was tolerated at the P1 position (IC 50 = 4.93 ± 0.79 μM); however, imidazole (28) and pyrimidine (29) were not preferred (IC 50 > 20 μM).

Next, the above identified favorable P1′, P2, P1, and P3/P4 substitutions were combined and the designed compounds were shown in Figure 5E . Compounds 36, 37, and 38 were the most potent leads with IC 50 values of 0.81 ± 0.24, 0.67 ± 0.15, Cellular Antiviral Activity of Noncovalent SARS-CoV-2 M pro Inhibitors. Next, compounds with potent enzymatic inhibition (IC 50 ≤ 1 μM) and low cellular cytotoxicity (CC 50 > 100 μM) were prioritized for the cellular antiviral assay with infectious SARS-CoV-2 in Vero E6 cells using the immunofluorescence assay as the primary assay ( Figure 6A ). ML188 (1) was included as a control. It was found that ML188 (1) was inactive in the antiviral assay (EC 50 > 20 μM), probably due to its incomplete inhibition of the M pro in the cellular content. Gratifyingly, compounds 20, 23, 37, 38, and 40 all had potent cellular antiviral activity with EC 50 values ranging from 0.82 to 4.54 μM. Compound 24 was less active (EC 50 = 13.06 ± 2.30 μM), possibly due to the poor cellular membrane permeability.

Given the potent antiviral activity and high selectivity index of these potent lead compounds, we then selected the noncovalent inhibitor 23 for further characterization. The two diastereomers of 23 were separated by reverse phase HPLC ( Figure 6B ). Both diastereomers were tested in the FRET-based enzymatic assay. GC376 was included as a positive control. It was found that 23R is the active diastereomer with an IC 50 value of 0.20 ± 0.01 μM, while the 23S diastereomer was not active (IC 50 > 20 μM) (Figure 6A). The stereochemistry of 23R was determined by the cocrystal structure with SARS-CoV-2 M pro as described in the following section. Compared with the parent compound ML188 (1), the optimized lead 23R had more than a 54-fold increase in enzymatic inhibition against SARS-CoV-2 M pro . Compound 23R also showed comparable potency against SARS-CoV M pro with an IC 50 value of 0.27 ± 0.03 μM. Neither ML188 (1) nor 23R inhibited the SARS-CoV-2 papain-like protease (PL pro ) (IC 50 > 20 μM) ( Figure 6A ), suggesting the inhibition of SARS-CoV-2 M pro by 23R is specific.

Next, the antiviral activity of 23R was tested against SARS-CoV-2 (USA-WA1/2020 isolate) in Vero E6 cells using the immunofluorescence assay. It was found that compound 23R had an EC 50 value of 1.27 μM ( Figure 6A ), which was similar to the antiviral potency of the covalent inhibitor GC376 (EC 50 = 1.51 μM). Compound 23R was also not cytotoxic to Vero E6 cells at up to 100 μM. In contrast, the parent compound ML188 (1) had no detectable antiviral activity when tested at up to 20 μM. To further confirm the antiviral activity of compound 23R, we performed a secondary antiviral assay in the human lung epithelial Calu-3 cell line, which endogenously expresses TMPRSS2 and is widely used as a physiological relevant cell line for SARS-CoV-2 infection. It was found that compound 23R inhibited SARS-CoV-2 (USA-WA1/2020 isolate) replication in Calu-3 cells with an EC 50 value of 3.03 μM, and it was not cytotoxic at up to 100 μM ( Figure 6C , D).

Profiling the Target Selectivity of 23R against Other Viral Cysteine Proteases and Host Proteases. One of the major challenges facing cysteine protease inhibitors is the target selectivity. 18, 19 It was recently reported that GC376 inhibits host cathepsins B and L in addition to SARS-CoV-2 M pro , 20 and GC376 analogs compound_1 and zyy16 that contained the aldehyde and cyanohydrin warheads, respectively, inhibit both calpain 1 and cathepsin K. 21 These results raised the concern of the selectivity of this class of covalent inhibitors. To profile the target selectivity of the lead compounds developed in this study, we selected compound 23R as a representative example of the noncovalent inhibitor. ML188 (1) and GC376 were included as controls. The compounds were tested against a panel of viral cysteine proteases including SARS-CoV M pro , MERS-CoV M pro , HCoV-OC43 M pro , EV-A71 3C pro , EV-D68 3C pro , EV-A71 2A pro , EV-D68 2A pro , and SARS-CoV-2 PL pro , as well as host cysteine proteases calpain 1, cathepsin K, cathepsin L, and serine protease trypsin. It was found that GC376 inhibited all the M pro and 3C pro tested including SARS-CoV-2 M pro , SARS-CoV M pro , MERS-CoV M pro , HCoV-OC43 M pro , EV-A71 3C pro , and EV-D68 3C pro (IC 50 ≤ 0.16 μM), but not the unrelated EV-A71 2A pro , EV-D68 2A pro , and SARS-CoV-2 PL pro (IC 50 > 50 μM) ( Figure 7A and Table S1 ). In addition, GC376 also inhibited host cysteine proteases calpain 1, Journal of Medicinal Chemistry pubs.acs.org/jmc Article cathepsin K, and cathepsin L (IC 50 ≤ 0.074 μM) but not the serine protease trypsin (IC 50 > 50 μM) ( Figure 7B and Table  S1 ). In contrast, the noncovalent inhibitor 23R developed in this study only selectively inhibited SARS-CoV-2 M pro and SARS-CoV M pro with high potency (IC 50 ≤ 0.27 μM) but not other viral proteases tested, which was similar to ML188 (1) ( Figure 7A and Table S1 ). Compound 23R showed weak inhibition against calpain 1 and cathepsin L with IC 50 values of 6.00 μM and 10.5 μM, respectively, corresponding to selectivity indexes of 40 and 70 with regard to SARS-CoV-2 M pro inhibition ( Figure 7B and Table S1 ).

Mechanism of Action of Noncovalent Inhibitor 23R in Inhibiting SARS-CoV-2 M pro . The mechanism of action was characterized using native mass spectrometry, the thermal shift-binding assay, and enzymatic kinetic studies (Figure 8 ). In the native mass spectrometry binding assay, compound 23R showed dose-dependent binding to SARS-CoV-2 M pro , similar to the positive control GC376, with a binding stoichiometry of one drug per monomer ( Figure 8A ). Similarly, compound 23R showed dose-dependent stabilization of the SARS-CoV-2 M pro in the thermal shift binding assay with an apparent K d value of 9.43 μM, a 9.3-fold decrease compared to ML188 (1) ( Figure  8B ). In the enzymatic kinetic studies, 23R was shown to be a noncovalent inhibitor with a K i value of 0.07 μM ( Figure 8C , D top and middle panels). In comparison, the K i for the parent compound ML188 (1) is 2.29 μM. The Lineweaver−Burk or double-reciprocal plot with different compound concentrations yielded an intercept at the Y-axis, suggesting that 23R is a competitive inhibitor similar to ML188 (1) ( Figure 8C , D bottom panel). Overall, the enzymatic kinetic studies confirmed that compound 23R is a noncovalent inhibitor of SARS-CoV-2 M pro .

X-ray Crystal Structure of SARS-CoV-2 M pro with 23R. Using X-ray crystallography, we successfully determined the binding pose of 23R with SARS-CoV-2 M pro at 2.6 Å resolution ( Figure 9A , Table S2 ). Electron density reveals the body of 23R extends throughout the substrate binding channel, with side chains occupying S1′, S1, S2, and a previously unexplored subpocket in between S2 and S4. The binding pose is similar to the previously solved structure of SARS-CoV M pro with ML188 (R) (PDB: 3V3M), 13 consistent with the similarities between the two compounds and between the two proteins ( Figure 9B ). The furyl moiety of 23R binds to a portion of the P1′ site, which normally accommodates small hydrophobic residues. While the furylamide carbonyl group of 23R does not insert into the oxyanion hole, it does form a bifurcated hydrogen bond with the apical residue of this oxyanion hole, Gly143. However, the furan ring oxygen is likely a weaker hydrogen bond acceptor than the amide oxygen, and it lies outside of the plane of Gly143's amide NH. Directly attached to the furylamide moiety is a P2 biphenyl group and a P1 pyridinyl ring. The P2 biphenyl group projects directly into the S2 pocket, which prefers hydrophobic residues such as leucine and phenylalanine. As expected, the P1 pyridinyl ring occupies the S1 pocket, which is known for its strict preference for glutamine. While most M pro inhibitors bear a pyrrolidinone glutamine mimetic at the P1 position, we determined that more hydrophobic residues can also bind to the S1 site and that hydrogen bond formation with His163 is critical for inhibition. 8 In this instance, the pyridinyl ring of 23R is nearly superimposable with the same moiety from calpain inhibitor XII ( Figure 9C ) forming a close (2.9 Å) hydrogen bond with His163. An amide bond connecting the pyridinyl ring to the α-methylbenzyl moiety forms a hydrogen bond with the main chain of Glu166. The benzyl ring of the αmethylbenzyl moiety is partially positioned in both the S2 and S4 pockets, a novel binding pose that has not been observed with existing M pro inhibitors. Normally, a substituent at this position would be expected to flip away from the enzyme core toward the solvent-exposed S3 pocket, which explains why P3 substitutions have little to no influence on the enzymatic inhibition. 4 However, the chirality and hydrophobic nature of the benzyl ring in 23R cause it to project toward the core near the S2 pocket, forcing Gln189 to rotate outward ( Figure 9D ). This conformation is reinforced by π-stacking interactions with the first phenyl of the biphenyl substituent. Notably, the binding pose of 23R features continuous intramolecular πstacking, where the phenyl is sandwiched by furan and benzyl groups, potentially contributing to its potent inhibition of M pro . Meanwhile, the S4 pocket remains largely unoccupied by 23R, leaving room for further improvement. In summary, the X-ray crystal structure of SARS-CoV-2 M pro in complex with 23R revealed two interesting structural features: (1) The P2 biphenyl is probably the longest substitution that can be accommodated in the S2 pocket, which is consistent with our design hypothesis. (2) The benzyl group from the terminal αmethylbenzyl fits in a pocket in between the S2 and S4 pockets, and this is a ligand-induced binding site that has not been previously explored. Although this is unexpected from the design perspective, this novel binding mode suggests that the new binding pocket in between S2 and S4 can be explored for inhibitor design.

The viral M pro is a high profile antiviral drug target, and several M pro inhibitors are now in animal model studies and human clinical trials. 6 Among the known M pro inhibitors, the majority are covalent inhibitors such as GC376 analogs that contain a pyrrolidone in the P1 position as a glutamine mimetic. Several structurally distinct compounds including ebselen, disulfiram, carmofur, PX-12, tideglusib, and shiknonin were claimed as M pro inhibitors 22,23 but were later proved to be promiscuous nonspecific cysteine protease inhibitors. 24, 25 In addition, noncovalent inhibitors such as ML188 (R) were developed and validated as SARS-CoV M pro inhibitors. 5, 13 Several follow up studies have been conducted to optimize the enzymatic potency of this series of compounds against SARS-CoV M pro and SARS-CoV-2 M pro . However, no significant improvement has been made, and ML188 (R) remains the only noncovalent inhibitor with moderate antiviral activity against SARS-CoV (EC 50 = 12.9 ± 0.7 μM). 14,15 Nevertheless, given the sequence and structural similarities between SARS-CoV and SARS-CoV-2 M pro , and the similar binding mode of ML188 (R) and calpain inhibitor XII, we hypothesize that ML188 (R) is a promising scaffold for structure-based drug design. In this study, we developed an expedited drug discovery approach for the design of noncovalent SARS-CoV-2 M pro inhibitors. The design approach couples the superimposed X-ray crystal structures with the one-pot Ugi 4CR synthetic methodology. We were able to improve the enzymatic inhibition potency of ML188 (1) by 54-fold from a focused library of 39 noncovalent inhibitors. This is a significant advantage compared to covalent inhibitors such as GC376, which involves at least a five-step synthesis. In addition, by introducing the chiral isocyanide, the diastereomer product can be conveniently separated by either silica gel column or Journal of Medicinal Chemistry pubs.acs.org/jmc Article reverse phase HPLC column, bypassing the need for an expensive chiral HPLC column. Target selectivity profiling showed that the noncovalent inhibitor 23R only selectively inhibits SARS-CoV-2 and SARS-CoV M pro , but not other viral proteases and host proteases including calpain 1, cathepsins L and K, and trypsin. In contrast, the covalent M pro inhibitor GC376 is not selective and inhibits host cysteine proteases, which might result in potential side effects. Furthermore, the X-ray crystal structure of SARS-CoV-2 M pro in complex with 23R reveals a ligand-induced binding pocket in between S2 and S4 sites that can be explored for drug design. Overall, using the expedited drug discovery approach, this study revealed a promising noncovalent M pro inhibitor 23R with a well characterized mechanism of action and potent cellular antiviral activity for further development.

Cell Lines and Viruses. VERO E6 cells (ATCC, CRL-1586) were cultured in Dulbecco's modified Eagle's medium (DMEM), supplemented with 5% heat inactivated FBS in a 37°C incubator with 5% CO 2 . SARS-CoV-2, isolate USA-WA1/2020 (NR-52281), was obtained through BEI Resources and propagated once on VERO E6 cells before it was used for this study. Studies involving SARS-CoV-2 were performed at the UTHSCSA biosafety level-3 laboratory by personnel wearing powered air purifying respirators.

Protein Expression and Purification. SARS CoV-2 main protease (M pro or 3CL) gene from strain BetaCoV/Wuhan/ WIV04/2019 and SARS-CoV main protease from strain CDC#200301157 in the pET29a(+) vector with E. coli codon optimization were ordered from GenScript (Piscataway, NJ). The M pro gene was then subcloned into pE-SUMO vector as described previously. 7, 8 The expression and purification of SARS-CoV and SARS-CoV-2 M pro with unmodified N-and C-termini were detailed in our previous publication. 8 The expression and purification of SARS CoV-2 papain-like protease (PL pro ) were also described in our previous publications. 7, 8, 24 The expression and purification of EV-A71 2A pro and 3C pro , EV-D68 2A pro and 3C pro were described in our previous publications. 24, 26 Cathepsin K and Cathepsin L were purchased from EMD Millipore (catalog #. 219461 and 219402, respectively).

Calpain 1 and trypsin were purchased from Sigma-Aldrich (catalog #. C6108 and T6763, respectively).

Peptide Synthesis. The SARS-CoV-2 M pro FRET substrate Dabcyl-KTSAVLQ/SGFRKME(Edans) was synthesized as described before. 7 The SARS-CoV-2 PL pro , EV-A71 2A pro and 3C pro , and EV-D68 2A pro and 3C pro FRET substrates were listed in our previous publication 24 and were synthesized by solid-phase synthesis through iterative cycles of coupling and deprotection using the previously optimized procedure. 27 General Chemical Methods. All chemicals were purchased from commercial vendors and used without further purification unless otherwise noted. 1 H and 13 C NMR spectra were recorded on a Bruker-400 or -500 NMR spectrometer. Chemical shifts are reported in parts per million referenced with respect to residual solvent (CD 3 OD) 3.31 ppm, (DMSO-d 6 ) 2.50 ppm, and (CDCl 3 ) 7.26 ppm or from internal standard tetramethylsilane (TMS) 0.00 ppm. The following abbreviations were used in reporting spectra: s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; dd, doublet of doublets; ddd, doublet of doublet of doublets. All reactions were carried out under N 2 atmosphere, unless otherwise stated. HPLC-grade solvents were used for all reactions. Flash column chromatography was performed using silica gel (230−400 mesh, Merck). High resolution mass spectra were obtained using an OrbitrapTM for all the compounds, obtained in an Ion Cyclotron Resonance (ICR) spectrometer. The purity was assessed by using Shimadzu UPLC with Shimdazu C18-AQ column (4.6 × 150 mm P/N #227-30767-05) at a flow rate of 1 mL/min; λ = 254 and 220 nm; mobile phase A, 0.1% trifluoroacetic acid in H 2 O, and mobile phase B, 0.1% trifluoroacetic acid in 90% CH 3 CN and 10% H 2 O. The gradients are 0−2 min 10% B, 2−15 min 10%−100% B, 15−18 min, 100% B, 18.1−20 min 10% B. All compounds submitted for testing were confirmed to be >95.0% purity by HPLC traces. All final products were characterized by proton and carbon NMR, HPLC, and HRMS.

General Procedure for Ugi-4CR Reaction.

Ug-4CR reaction was performed according to the reported procedure with modifications. 13 Amine (1.0 equiv) and aldehyde (1.0 equiv) were mixed in methanol (10 mL) and stirred at room temperature for 30 min. Then carboxylic acid (1.0 equiv) and isocyanide (1.0 equiv) were added sequentially and the resulting mixture was stirred at room temperature overnight. After that, the solvent was removed under reduced pressure and the crude product was purified with flash silica gel chromatography (methanol in dichloromethane 1−5% or acetone in hexane 30−80%). General Procedures for the Synthesis of Compounds 24, 28, 33, 35, and 37 by TFA Deprotection. To a solution of N-trityl-protected Ugi-4CR compound in dichloromethane (5 mL) was added TFA (1 mL). The mixture was stirred at room temperature for 2 h, and the solvent was removed under reduced pressure. The crude mixture was diluted in dichloromethane and purified by silica gel flash column chromatography (ammonia 10% methanol in dichloromethane 10− 15%) to give the final product.

Procedure for the Synthesis of Compound 18 by Suzuki− Miyamura Cross-coupling.

To solution of 2-[N-(4-bromophenyl)-1-(furan-2-yl)formamido]-N-[(1S)-1-phenylethyl]-2-(pyridin-3-yl)acetamide (1 mmol) and furan-2-boronic acid (1 mmol) in 1,4-dioxane in a microwave reaction vial was added an aqueous solution of K 2 CO 3 (4 mmol). The resulting solution was purged with N 2 for 5 min. The catalyst, Pd(PPh 3 ) 4 (0.1 mmol), was added in one portion. The vial was capped and heated to 140°C for 30 min with microwave irradiation. After cooling down to room temperature, the reaction solution was diluted with dichloromethane and extracted with water, followed by brine. The organic layer was dried over MgSO 4 , filtrated, and concentrated under reduced pressure. The crude product was purified by silica gel flash column chromatography (methanol in dichloromethane 1−5%) to give the final product.

Procedure for the Synthesis of 4-(Thiophen-2-yl)aniline by Suzuki−Miyamura Cross-coupling.

The starting material 4-(thiophen-2-yl)aniline used for the synthesis of compound 19 was prepared using the following procedure. To a suspension of thiophene-2-boronic acid (1.0 mmol) and sodium carbonate (1.0 mmol) in toluene/methanol (4:1, 40 mL) was added 4-bromoaniline (1.0 mmol) To solution of N-(3-phenylpropyl)formamide (2 mmol) in dichloromethane (50 mL) was added triethylamine (4.8 mmol). The solution was cooled to approximately −10°C using an ethanol ice bath. Triphosgene (0.4 mmol) was added to the stirring mixture. The resulting mixture was stirred at −10°C for 10 min. In a separate 250 mL round-bottomed flask, 4-aminobiphneyl (2 mmol) and 3pyridinecarboxaldehyde (2 mmol) were mixed in methanol (100 mL) and stirred at room temperature for 30 min. Then carboxylic acid (2 mmol) and the resulting isocyanide solution (1.0 equiv) were added sequentially, and the resulting mixture was stirred at room temperature overnight. After that, the solvent was removed under reduced pressure and the crude product was purified with flash silica gel chromatography (methanol in dichloromethane 1−5%) to give the final product. a. N-tert-Butyl-2-[N-(4-tert-butylphenyl)-1-(furan-2-yl)formamido]-2-(pyridin-3-yl)acetamide (1) . Light yellow solid, 81% yield. 1 MeOD-d 4 ) δ 169.5, 161.4, 153.8, 152.2, 149.9, 147.4, 146.7, 140.3,  139.4, 137.4, 134.5, 132.2, 131.9, 127.1, 125.5, 123.1, 123.0, 118.4,  116.4, 116.2, 112.3, 65.5 168.9, 158.2, 151.3, 151.1, 148.8, 146.3, 145.3,  139.1, 137.6, 136.5, 130.7, 128.1, 127.1, 126.7, 125.3, 122.7 m. 2-[N-(4-tert-Butylphenyl)-1-(furan-2-yl)formamido]-N-[(1S)-1-phenylethyl]-2-(pyridin-3-yl)acetamide (13) . Light yellow solid. 84% yield. 1 168.1, 167.9, 158.2, 158.1, 151.3, 151.2,  151.0, 148.7, 146.3, 146.2, 145.2, 145.2, 144.3, 144.0, 137.5, 137.4,  136.4, 136.3, 130.8, 130.4, 128.1, 128.0, 126.6, 126.5, 126.1, 125.7 Hz, 9H). 13 13 Native mass spectrometry (MS) was performed using a Q-Exactive HF quadrupole-Orbitrap mass spectrometer with the Ultra-High Mass Range research modifications (Thermo Fisher Scientific). Samples were ionized using nanoelectrospray ionization in positive ion mode using 1.0 kV capillary voltage at a 150°C capillary temperature. The samples were all analyzed with a 1,000−25,000 m/z range, the resolution set to 30,000, and a trapping gas pressure set to 3. Between 10 and 50 V of source fragmentation was applied to all samples to aid in desolvation. Data were deconvolved and analyzed with UniDec. 28 Enzymatic Assays. The main protease (M pro ) enzymatic assays were carried out in M pro reaction buffer containing 20 mM HEPES pH 6.5, 120 mM NaCl, 0.4 mM EDTA, 20% glycerol, and 4 mM DTT, and the SARS-CoV-2 papain-like protease (PL pro ) enzymatic assays were carried out in PL Pro reaction buffer containing 50 mM HEPES, pH7.5, 0.01% triton-100, and 5 mM DTT. The percentage of inhibition and enzymatic IC 50 values were calculated as previously described. 7, 8 Briefly, the assay was performed in 96-well plates with 100 μL of 100 nM M pro protein or 200 nM PL Pro protein in their respective reaction buffers. Then 1 μL testing compound at various concentrations was added to each well and incubated at 30°C for 30 min. The enzymatic reaction was initiated by adding 1 μL of 1 mM corresponding FRET substrate (the final substrate concentration is 10 μM). The reaction was monitored in a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30°C for 1 h. The initial velocity of the enzymatic reaction with and without testing compounds was calculated by linear regression for the first 15 min of the kinetic progress curve.

For the Morrison plot, 10 μL of 100 nM SARS-CoV-2 M pro protein was added to 190 μL of M pro reaction buffer containing testing compound and the FRET substrate, and the reaction was monitored for 2 h. The final FRET substrate concentration in this assay is 20 μM. Detailed curve fitting and K I determination were described previously. 7, 8 For Michaelis−Menten and Lineweaver−Burk plots, assay was carried out as follows: 50 μL of 50 μM M pro protein was added to 50 μL of reaction buffer containing testing compound and various concentrations of FRET substrate to initiate the enzyme reaction. The initial velocity of the enzymatic reaction with and without testing compounds was calculated by linear regression for the first 15 min of the kinetic progress curve, plotted against substrate concentrations in Prism 8 with the Michaelis−Menten equation.

Cathepsin K and cathepsin L enzymatic assay was carried out as follows: cathepsin K or cathepsin L was activated by incubating in reaction buffer [20 mM sodium acetate, 1 mM EDTA, and 5 mM DTT (pH 5.5)] for 30 min at 30°C. Upon activation, the assay was assembled in 96-well plates with 100 μL of cathepsin K at 200 pM or cathepsin L at 300 pM in reaction buffer. Then, 1 μL of testing compound at various concentrations was added to each well and incubated at 30°C for 30 min. The enzymatic reaction was initiated by adding 1 μL of FRET substrate Z-Phe-Arg-AMC (BACHEM, catalog #. 4003379.0050) (the final substrate concentration is about 5 μM for cathepsin K and 1 μM for cathepsin L). The reaction was monitored in a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30°C for 1 h. The IC 50 values were calculated as described in the previous section.

Calpain 1 enzymatic assay was carried out as follows: 1 μL of 1 μg/ μL calpain 1 protein was added to 100 μL of calpain I reaction buffer [50 mM HEPES, 50 mM NaCl, and 10 mM DTT and 5 mM CaCl 2 (pH 7.5)]; the enzymatic reaction was iniated by adding 1 μL of 4 mM N-succinyl-Leu-Leu-Val-Tyr-7-amido-4-methylcoumarin substrate (Sigma-Aldrich catalog #. S6510). The reaction was monitored with a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30°C for 1 h. The IC 50 values were calculated as described in the previous section.

Trypsin enzymatic assay was carried out in a 50 μL volume containing 100 nM trypsin in 50 mM HEPES (pH7.6) reaction buffer, 100 μM Bz-Arg-AMC·HCl (BACHEM, catalog no. 4002540.0050), and serial concentrations of test compounds in duplicate. The reaction was monitored with a Cytation 5 image reader with filters for excitation at 360/40 nm and emission at 460/40 nm at 30°C for 1 h. The IC 50 values were calculated as described in the previous section.

Differential Scanning Fluorimetry (DSF). The thermal shift binding assay (TSA) was carried out using a Thermal Fisher QuantStudio 5 Real-Time PCR System as described previously. 7, 8, 29 Briefly, 3 μM SARS-CoV-2 M pro protein in M pro reaction buffer was incubated with various concentrations of compound ML188 or 23R at 30°C for 30 min. 1X SYPRO orange dye was added, and the fluorescence of the well was monitored under a temperature gradient range from 20 to 90°C with a 0.05°C/s incremental step. Measured T m was plotted against compound concentration with one-site binding function in Prism 8.

Cytotoxicity Measurement. Evaluation of the cytotoxicity of compounds was carried out using the neutral red uptake assay. 30 Immunofluorescence Assay. Antiviral immunofluorescence assay was carried out as previously described. 8 Briefly, Vero E6 cells in 96-well plates (Corning) were infected with SARS-CoV-2 (USA-WA1/2020 isolate) at MOI of 0.05 in DMEM supplemented with 1% FBS. Immediately before the viral inoculation, the tested compounds in a 3-fold dilution concentration series were also added to the wells in triplicate. The infection proceeded for 48 h without the removal of the viruses or the compounds. The cells were then fixed with 4% paraformaldehyde, permeabilized with 0.1% Triton-100, blocked with DMEM containing 10% FBS, and stained with a rabbit monoclonal antibody against SARS-CoV-2 NP (GeneTex, GTX635679) and an Alexa Fluor 488-conjugated goat antimouse secondary antibody (ThermoFisher Scientific). Hoechst 33342 was added in the final step to counterstain the nuclei. Fluorescence images of approximately ten thousand cells were acquired per well with a 10× objective in a Cytation 5 (BioTek). The total number of cells, as indicated by the nuclei staining, and the fraction of the infected cells, as indicated by the NP staining, was quantified with the cellular analysis module of the Gen5 software (BioTek).

Antiviral Assay in Calu-3 Cells. Calu-3 cells (ATCC, HTB-55) grown in Minimal Eagles Medium supplemented with 1% nonessential amino acids, 1% penicillin/streptomycin, and 10% FBS are plated in 384 well plates. The next day, 50 nL of drug suspended in DMSO is added as an 8-pt dose response with 3-fold dilutions between test concentrations in triplicate, starting at 40 μM final concentration. The negative control (DMSO, n = 32) and positive control (10 μM Remdesivir, n = 32) are included on each assay plate. Calu3 cells are pretreated with controls and test drugs (in triplicate) for 2 h prior to infection. In BSL3 containment, SARS-CoV-2 (isolate USA-WA1/2020) diluted in serum free growth medium is added to plates to achieve an MOI = 0.5. Cells are incubated continuously with drugs and SARS-CoV-2 for 48 h. Cells are fixed and then immunstained with anti-dsRNA (J2), and nuclei are counterstained with Hoechst 33342 for automated microscopy. Automated image analysis quantifies the number of cells per well (toxicity) and the percentage of infected cells (dsRNA+ cells/cell number) per well. SARS-CoV-2 infection at each drug concentration was normalized to aggregated DMSO plate control wells and expressed as percentage-ofcontrol (POC = % Infection sample /Avg % Infection DMSO cont ). A nonlinear regression curve fit analysis (GraphPad Prism 8) of POC infection and cell viability versus the log 10 transformed concentration values to calculate EC 50 values for infection and CC 50 values for cell viability. Selectivity index (SI) was calculated as a ratio of drug's CC 50 and EC 50 values (SI = CC 50 /IC 50 ).

M pro Crystallization and Structure Determination. 23R was added to 20 mg/mL SARS-CoV-2 M pro to a final concentration of 1.75 mM and incubated overnight at 4°C. This mixture was then diluted 4-fold with protein stock buffer (20 mM Tris pH 7.5, 200 mM NaCl, 1 mM DTT) and then spun down at 13,000g for 1 min to remove precipitate. Crystals were grown by mixing the proteininhibitor sample with an equal volume of crystallization buffer (20% PEG 3350, 0.2 M NaF) in a vapor diffusion, hanging drop apparatus. Crystals were then transferred to a drop with crystallization buffer containing 5 mM 23R for 1 h, followed by a brief soaking in a cryoprotectant solution of 30% PEG 3350 and 15% glycerol with 2 mM 23R. Crystals were then flash frozen in liquid nitrogen for X-ray diffraction.

X-ray diffraction data for the SARS-CoV-2 M pro structures were collected on the SBC 19-ID beamline at the Advanced Photon Source (APS) in Argonne, IL, and processed with the HKL3000 software suite. The CCP4 versions of MOLREP 32 was used for molecular replacement using a previously solved SARS-CoV-2 M pro structure, 6YB7. Structural refinement was performed using REFMAC5 33 and COOT. 34 The crystallographic statistics is shown in Supporting Information 

Hz, 1H), 6.15 (s, 1H), 5.24 (d, J = 3.5 Hz, 1H), 1.22 (s, 9H), 1.19 (s, 9H). 13 C NMR (101 MHz

15 (s, 1H), 5.26 (d, J = 3.6 Hz, 1H), 3.99−3.76 (m, 1H), 1.20 (s, 9H), 1.07 (d, J = 6.6 Hz, 3H), 0.95 (d, J = 6.5 Hz, 3H). 13 C NMR (101 MHz, DMSO-d 6 )

Hz, 1H), 7.37 (dt, J = 8.0, 1.9 Hz, 1H), 7.26−7.19 (m, 2H), 7.25− 6.94 (br s, 1H), 7.16−7.09 (m, 2H)

418.2125 (found). HPLC purity: 96%. d. 2-[N-(4-tert-Butylphenyl)-1

Hz, 2H), 1.35−1.23 (m, 7H), 1.21 (s, 9H), 0.86 (s, 9H). 13 C NMR (101 MHz

Hz, 1H), 7.70−7.65 (m, 1H), 7.37 (dt, J = 7.9, 2.0 Hz, 1H), 7.28− 7.18 (m, 2H), 7.25−6.94 (br s, 1H) 7.18−7.06 (m, 2H)

Hz, 1H), 1.86−1.67 (m, 2H), 1.65−1.31 (m, 5H), 1.30−1.21 (m, 1H), 1.20 (s, 9H). 13 C NMR (101 MHz

Hz, 1H), 7.67 (dd, J = 1.7, 0.7 Hz, 1H), 7.38 (dt, J = 7.9, 2.0 Hz, 1H), 7.28−7.02 (br s, 1H), 7.25−7.19 (m, 2H), 7.17−7.10 (m, 2H)

Hz, 0.5H), 5.05−4.91 (m, 1H), 2.48−2.31 (m, 1H), 1.84−1.57 (m, 5H), 1.39-1.10 (m, 5H), 1.31 (dd, J = 41.17, 7.02 Hz, 3H) 13 C NMR (101 MHz

Light brown solid. 35% yield. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.80 (dd

Hz, 1H), 8.66−8.45 (m, 2H), 7.82 (dt, J = 8.1, 1.9 Hz, 1H), 7.71 (dddd, J = 24.9, 6.9, 1.8, 0.8 Hz, 2H), 7.64−7.46 (m, 3H), 7.45−7.07 (m, 7H), 6.96 (ddd, J = 5

Light yellow solid. 81% yield. 1 H NMR (500 MHz

−7.31 (m, 3H), 7.30−7.14 (m, 4H), 7.14−7.05 (m, 3H), 6.40− 6.28 (m, 2H), 5.63−5.69 (m, 0.5H), 5.58−5.54 (m, 0.5H), 5.07−4.96 (m, 1H), 1.39 (d, J = 7.1 Hz, 1.5H)

Yellow solid. 80% yield. 1 H NMR (400 MHz

Hz, 1H), 8.37 (d, J = 51.9 Hz 1H), 8.34 (dd, J = 12.0, 4.4 Hz, 1H), 7.72−7.66 (m, 1H), 7.57−7.30 (m, 7H), 7.30−7.12 (m, 4H), 7.11− 7.05 (m, 2 H)

Hz, 1H), 1.39 (d, J = 7.0 Hz, 1.5H), 1.26 (d, J = 7.0 Hz, 1.5H). 13 C NMR (101 MHz

Yellow solid. 88% yield. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.77 (dd

Hz, 1H), 8.65−8.59 (m, 1H), 8.46-8.27 (m, 2H), 7.97−7.88 (m, 3H)

−7.78 (m, 1H), 7.68 (ddd, J = 7.6, 1.7, 0.8 Hz, 1H), 7.57−7.00 (m, 10H)

White solid. 80% yield. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.71 (dd

White solid. 89% yield. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.75 (dd

27 (d, J = 7.0 Hz, 1.5H). 13 C NMR (101 MHz, DMSO-d 6 ) δ 168.1, 167.9

Hz, 1H), 8.43 (d, J = 2.3 Hz, 1H), 8.35 (dd, J = 4.8, 1.6 Hz, 1H), 7.71−7.66 (m, 1H), 7.66−7.61 (m, 2H), 7.60−7.52 (m, 2H)

DMSO-d6)

White solid, 45% yield. 1 H NMR (500 MHz, DMSO-d6) δ 8.75 (d, J = 7

White solid. 38% yield. 1 H NMR (500 MHz, DMSO-d 6 ) δ 12.76 (s, 1H)

Hz, 1H), 6.40 (s, 1H), 5.53 (s, 1H), 5.03 (p, J = 7.2 Hz, 1H), 1.26 (d, J = 7.0 Hz, 3H). 13 C NMR (126 MHz

Light yellow solid. 82% yield. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.83 (dd, J = 7.7, 5.7 Hz, 1H), 8.56−8.26 (m, 3H), 7.65−7.45 (m, 5H), 7.44−7.06 (m, 11H), 6.35 (d, J = 11.2 Hz, 1H), 5.88−5.77 (m, 1H), 5.13−4.94 (m, 1H), 1.40 (d, J = 7.0 Hz, 1.5H), 1.28 (d, J = 7.0 Hz, 1.5H). 13 C NMR (101 MHz

Yellow solid. 85% yield. 1 H NMR (400 MHz

Hz, 1H), 8.57−8.23 (m, 3H), 7.69−7.49 (m, 5H), 7.48−7.32 (m, 6H)

DMSO-d 6 ) δ 167.8, 167.6, 156.9

33 (dd, J = 3.6, 1.7 Hz, 1H), 6.28 (s, 1H), 5.39 (d, J = 3.6 Hz, 1H), 1.22 (s, 9H), 1.14 (s, 9H). 13 C NMR (126 MHz, DMSO-d 6 )

2. C 24 H 30 N 4 O 3

furan-2-yl)formamido)-2-(pyridin-3-yl)-N-(2,4,4-trimethylpentan-2-yl)acetamide (31). Light yellow solid

Hz, 6H), 0.87 (s, 9H). 13 C NMR (101 MHz

400 MHz, DMSO-d 6 ) δ 8.35 (d, J = 20.6 Hz, 2H), 8.24 (d, J = 7.0 Hz, 1H), 7.68 (dd, J = 1.7, 0.7 Hz, 1H), 7.66−7.60 (m, 2H), 7.55 (d, J = 8.1 Hz, 2H), 7.51-7.12 (br s, 1H), 7.50−7.29 (m, 5H), 7.16 (dd, J = 7.9, 4.7 Hz, 1H)

White solid. 44% yield. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.38 (d, J = 2.3 Hz, 1H), 8.33 (dd

)formamido)-N-cyclohexyl-2-(pyridin-3-yl)acetamide (34). White solid. 83% yield. 1 H NMR (500 MHz

White solid. 42% yield. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.40 (d, J = 2.3 Hz, 1H)

−7.63 (m, 2H), 7.59 (d, J = 7.2 Hz, 2H)

Hz, 1H), 6.26 (s, 1H), 5.56 (s, 1H), 3.67-3.57 (m, 1H), 1.86−1.48 (m, 5H), 1.35−1.16 (m, 3H), 1.15−0.96 (m, 2H). 13 C NMR (126 MHz

Yellow solid. 76% yield. 1 H NMR (400 MHz, DMSO-d 6 ) δ 8.69 (dd

Hz, 1H), 7.74−7.60 (m, 1H), 7.46−7.29 (m, 3H), 7.28−6.96 (m, 7H)

−1.07 (m, 5H), 1.31 (dd, J = 47.0 7.0 Hz, 3 H) 13 C NMR

-(pyrazin-2-yl)acetamide (37)

Journal of Medicinal Chemistry pubs

2. C 30 H 26 N 6 O 2

Yellow solid. 83% yield. 1 H NMR (500 MHz, DMSO-d 6 ) δ 8.79 (dd

(calculated), 503.2078 (found). HPLC purity: 100%. ao. 2-(N-{[1,1′-Biphenyl]-4-yl}-1-(furan-2-yl)formamido)-N-(2,2-diphenylethyl)-2-(pyrazin-2-yl)acetamide (39). Yellow solid

−7.42 (m, 2H), 7.38−7.33 (m, 1H), 7.32−7.10 (m, 12H), 7.05 (dt, J = 7.9, 2.0 Hz, 1H), 6.96 (dd, J = 8.0, 4.8 Hz, 1H), 6.33 (dd, J = 3.6, 1.7 Hz, 1H), 6.21 (s, 1H), 5.52 (dd, J = 3.6, 0.8 Hz, 1H), 4.23 (t, J = 7.9 Hz, 1H), 4.06−3.90 (m, 1H), 3.73−3.57 (m, 1H). 13 C NMR (126 MHz

Hz, 1H), 3.08 (q, J = 6.6 Hz, 2H), 2.48−2.39 (m, 2H), 1.69−1.55 (m, 2H). 13 C NMR (101 MHz

Ugi-4CR, Ugi four-component reaction

COVID-19: drug targets and potential treatments

SARS-CoV-2 Mpro inhibitors and activitybased probes for patient-sample imaging

Drug development and medicinal chemistry efforts toward SARS-coronavirus and Covid-19 therapeutics

GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease

Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against M(pro) and cathepsin L. Sci. Adv. 2020, 6, eabe0751

3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice

Efficacy of a 3C-like protease inhibitor in treating various forms of acquired feline infectious peritonitis

Reversal of the progression of fatal coronavirus infection in cats by a broad-spectrum coronavirus protease inhibitor

Discovery, synthesis, and structure-based optimization of a series of N-(tert-butyl)-2-(Narylamido)-2-(pyridin-3-yl) acetamides (ML188) as potent noncovalent small molecule inhibitors of the severe acute respiratory syndrome coronavirus (SARS-CoV) 3CL protease

Discovery of N-(benzo[1,2,3]triazol-1-yl)-N-(benzyl)acetamido)-phenyl) carboxamides as severe acute respiratory syndrome coronavirus (SARS-CoV) 3CLpro inhibitors: Identification of ML300 and noncovalent nanomolar inhibitors with an induced-fit binding

An automatic pipeline for the design of irreversible derivatives identifies a po t en t S A R S-Co V -2 M p r o inh i bi to r

Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors

Exploring ugi-azide fourcomponent reaction products for broad-spectrum influenza antivirals with a high genetic barrier to drug resistance

Can cysteine protease cross-class inhibitors achieve selectivity?

Challenges for targeting SARS-CoV-2 proteases as a therapeutic strategy for COVID-19

Application of dually activated michael acceptor to the rational design of reversible covalent inhibitor for enterovirus 71 3C protease

Structure of M(pro) from SARS-CoV-2 and discovery of its inhibitors

Crystal structure of SARS-CoV-2 main protease in complex with the natural product inhibitor shikonin illuminates a unique binding mode

PX-12, tideglusib, and shikonin are nonspecific promiscuous SARS-CoV-2 main protease inhibitors

Evaluation of SARS-CoV-2 3C-like protease inhibitors using selfassembled monolayer desorption ionization mass spectrometry

Validating enterovirus D68-2A(pro) as an antiviral drug target and the discovery of telaprevir as a potent D68− 2A(pro) inhibitor

Specific binding of adamantane drugs and direction of their polar amines in the pore of the influenza M2 transmembrane domain in lipid bilayers and dodecylphosphocholine micelles determined by NMR spectroscopy

Bayesian deconvolution of mass and ion mobility spectra: from binary interactions to polydisperse ensembles

The in vitro antiviral activity of lactoferrin against common human coronaviruses and SARS-CoV-2 is mediated by targeting the heparan sulfate coreceptor

Neutral red uptake assay for the estimation of cell viability/cytotoxicity

Pharmacological characterization of the spectrum of antiviral activity and genetic barrier to drug resistance of M2-S31N channel blockers

MOLREP: an automated program for molecular replacement

Coot: model-building tools for molecular graphics

. We thank Michael Kemp for assistance with crystallization and X-ray diffraction data collection. We also thank the staff members of the Advanced Photon Source of Argonne National Laboratory, particularly those at the Structural Biology Center (SBC), with X-ray diffraction data collection. SBC-CAT is operated by UChicago Argonne, LLC, for the U.S. Department of Energy, Office of Biological and Environmental Research under contract DE-AC02-06CH11357. The SARS-CoV-2 experiments were supported by a COVID-19 pilot grant from UTHSCSA and NIH grant AI151638 to Y.X. SARS-Related Coronavirus 2, Isolate USA-WA1/2020 (NR-52281) was deposited by the Centers for Disease Control and Prevention and obtained through BEI Resources, NIAID, NIH.